By Giulia Petroni 
 

The European Union on Wednesday approved Danaher Corp.'s (DHR) acquisition of GE Healthcare Life Sciences' biopharma business, subject to conditions.

The European Commission said Danaher committed to sell businesses that posed competition concerns. The acquisition is conditional on Danaher's compliance.

In February, General Electric Co. (GE) agreed to sell the business to Danaher for about $21 billion.

Both Danaher and the GE Healthcare Life Sciences' biopharma business are active in the manufacturing of products and services used in bioprocessing industries and compete in other life-sciences areas.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

(END) Dow Jones Newswires

December 18, 2019 13:12 ET (18:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
General Electric (NYSE:GE)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more General Electric Charts.
General Electric (NYSE:GE)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more General Electric Charts.